De-Risking The AAV Production By Working With An End-To-End CDMO

By Artur Padzik, Ph.D., AAV Technology Manager at 3PBIOVIAN

The rapid and exponential growth of gene therapies has underscored the critical role of adeno-associated virus (AAV) vectors in delivering transformative treatments. AAVs have emerged as the preferred vectors for addressing monogenic disorders like hemophilia and spinal muscular atrophy (SMA), and they hold promising potential for treating more widespread, high-prevalence diseases in the future.

As this therapeutic landscape evolves, Contract Development and Manufacturing Organizations (CDMOs) such as 3PBIOVIAN are playing a pivotal role in advancing AAV-based therapies from concept to clinic. However, the path to successful AAV production is complex, requiring an optimal balance between high productivity, uncompromising quality, and cost-efficiency. Identifying and mitigating risk factors across the AAV manufacturing workflow is essential to empower CDMOs in scaling safely and sustainably, ultimately accelerating the delivery of next-generation gene therapies.